Literature DB >> 25875323

Negotiating structural vulnerability following regulatory changes to a provincial methadone program in Vancouver, Canada: A qualitative study.

Ryan McNeil1, Thomas Kerr2, Solanna Anderson3, Lisa Maher4, Chereece Keewatin5, M J Milloy2, Evan Wood2, Will Small6.   

Abstract

While regulatory frameworks governing methadone maintenance therapy (MMT) require highly regimented treatment programs that shape treatment outcomes, little research has examined the effects of regulatory changes to these programs on those receiving treatment, and located their experiences within the wider context of social-structural inequities. In British Columbia (BC), Canada, provincial regulations governing MMT have recently been modified, including: replacing the existing methadone formulation with Methadose(®) (pre-mixed and 10 times more concentrated); prohibiting pharmacy delivery of methadone; and, prohibiting pharmacies incentives for methadone dispensation. We undertook this study to examine the impacts of these changes on a structurally vulnerable population enrolled in MMT in Vancouver, BC. Qualitative interviews were conducted with 34 people enrolled in MMT and recruited from two ongoing observational prospective cohort studies comprised of drug-using individuals in the six-month period in 2014 following these regulatory changes. Interview transcripts were analysed thematically, and by drawing on the concept of 'structural vulnerability'. Findings underscore how these regulatory changes disrupted treatment engagement, producing considerable health and social harms. The introduction of Methadose(®) precipitated increased withdrawal symptoms. The discontinuation of pharmacy delivery services led to interruptions in MMT and co-dispensed HIV medications due to constraints stemming from their structural vulnerability (e.g., poverty, homelessness). Meanwhile, the loss of pharmacy incentives limited access to material supports utilized by participants to overcome barriers to MMT, while diminishing their capacity to assert some degree of agency in negotiating dispensation arrangements with pharmacies. Collectively, these changes functioned to compromise MMT engagement and increased structural vulnerability to harm, including re-initiation of injection drug use and participation in high-risk income-generating strategies. Greater attention to the impacts of social-structural inequities on MMT engagement is needed when modifying MMT programs, especially as other jurisdictions are adopting similar changes. Comprehensive environmental supports should be provided to minimize adverse outcomes during transitional periods.
Copyright © 2015 Elsevier Ltd. All rights reserved.

Entities:  

Keywords:  Canada; Drug policy; Drug treatment; Health policy; Incentives; Methadone maintenance treatment; Methadose(®); Structural vulnerability

Mesh:

Substances:

Year:  2015        PMID: 25875323      PMCID: PMC4423784          DOI: 10.1016/j.socscimed.2015.04.008

Source DB:  PubMed          Journal:  Soc Sci Med        ISSN: 0277-9536            Impact factor:   4.634


  49 in total

1.  Addiction treatment-related employment barriers: the impact of methadone maintenance.

Authors:  Lindsey Richardson; Evan Wood; Julio Montaner; Thomas Kerr
Journal:  J Subst Abuse Treat       Date:  2012-02-01

2.  Structural vulnerability and hierarchies of ethnicity and citizenship on the farm.

Authors:  Seth M Holmes
Journal:  Med Anthropol       Date:  2011-07

3.  Methadone as social control: institutionalized stigma and the prospect of recovery.

Authors:  Julie Harris; Karen McElrath
Journal:  Qual Health Res       Date:  2012-01-09

4.  Increases in the availability of prescribed opioids in a Canadian setting.

Authors:  B Nosyk; B D L Marshall; B Fischer; J S G Montaner; E Wood; T Kerr
Journal:  Drug Alcohol Depend       Date:  2012-04-04       Impact factor: 4.492

5.  Structural vulnerability and health: Latino migrant laborers in the United States.

Authors:  James Quesada; Laurie Kain Hart; Philippe Bourgois
Journal:  Med Anthropol       Date:  2011-07

6.  Interdisciplinary mixed methods research with structurally vulnerable populations: case studies of injection drug users in San Francisco.

Authors:  Andrea M Lopez; Philippe Bourgois; Lynn D Wenger; Jennifer Lorvick; Alexis N Martinez; Alex H Kral
Journal:  Int J Drug Policy       Date:  2013-01-09

7.  Changes in the characteristics and levels of comorbidity among new patients into methadone maintenance treatment program in British Columbia during its expansion period from 1998-2006.

Authors:  Behnam Sharif; Bohdan Nosyk; Huiying Sun; David C Marsh; Aslam Anis
Journal:  Subst Use Misuse       Date:  2013-06-10       Impact factor: 2.164

8.  "Eyes that don't see, heart that doesn't feel": coping with sex work in intimate relationships and its implications for HIV/STI prevention.

Authors:  Jennifer L Syvertsen; Angela M Robertson; María Luisa Rolón; Lawrence A Palinkas; Gustavo Martinez; M Gudelia Rangel; Steffanie A Strathdee
Journal:  Soc Sci Med       Date:  2013-03-18       Impact factor: 4.634

Review 9.  The use of incentives to reinforce medication adherence.

Authors:  Anthony DeFulio; Kenneth Silverman
Journal:  Prev Med       Date:  2012-05-02       Impact factor: 4.018

10.  Trends in the population prevalence of people who inject drugs in US metropolitan areas 1992-2007.

Authors:  Barbara Tempalski; Enrique R Pouget; Charles M Cleland; Joanne E Brady; Hannah L F Cooper; H Irene Hall; Amy Lansky; Brooke S West; Samuel R Friedman
Journal:  PLoS One       Date:  2013-06-05       Impact factor: 3.240

View more
  40 in total

1.  Antiretroviral Therapy Interruption Among HIV Postive People Who Use Drugs in a Setting with a Community-Wide HIV Treatment-as-Prevention Initiative.

Authors:  Ryan McNeil; Thomas Kerr; Bill Coleman; Lisa Maher; M J Milloy; Will Small
Journal:  AIDS Behav       Date:  2017-02

Review 2.  The experience of initiating injection drug use and its social context: a qualitative systematic review and thematic synthesis.

Authors:  Andy Guise; Danielle Horyniak; Jason Melo; Ryan McNeil; Dan Werb
Journal:  Addiction       Date:  2017-09-29       Impact factor: 6.526

3.  Willingness to take buprenorphine/naloxone among people who use opioids in Vancouver, Canada.

Authors:  Sarah A Weicker; Kanna Hayashi; Cameron Grant; M-J Milloy; Evan Wood; Thomas Kerr
Journal:  Drug Alcohol Depend       Date:  2019-10-25       Impact factor: 4.492

Review 4.  The Syndemic of Opioid Misuse, Overdose, HCV, and HIV: Structural-Level Causes and Interventions.

Authors:  David C Perlman; Ashly E Jordan
Journal:  Curr HIV/AIDS Rep       Date:  2018-04       Impact factor: 5.071

5.  Patient-centred care in opioid agonist treatment could improve outcomes.

Authors:  Thomas D Brothers; Matthew Bonn
Journal:  CMAJ       Date:  2019-04-29       Impact factor: 8.262

6.  A fragmented code: The moral and structural context for providing assistance with injection drug use initiation in San Diego, USA.

Authors:  Andy Guise; Jason Melo; Maria Luisa Mittal; Claudia Rafful; Jazmine Cuevas-Mota; Peter Davidson; Richard S Garfein; Dan Werb
Journal:  Int J Drug Policy       Date:  2018-03-07

7.  "Bed Bugs and Beyond": An ethnographic analysis of North America's first women-only supervised drug consumption site.

Authors:  Jade Boyd; Jennifer Lavalley; Sandra Czechaczek; Samara Mayer; Thomas Kerr; Lisa Maher; Ryan McNeil
Journal:  Int J Drug Policy       Date:  2020-04-02

8. 

Authors:  Matias Raski; Christy Sutherland; Rupinder Brar
Journal:  Can Fam Physician       Date:  2020-11       Impact factor: 3.275

9.  From methadone to Methadose: Lessons learned from methadone formulation change in British Columbia.

Authors:  Matias Raski; Christy Sutherland; Rupinder Brar
Journal:  Can Fam Physician       Date:  2020-11       Impact factor: 3.275

10.  'Crisis' and 'everyday' initiators: A qualitative study of coercion and agency in the context of methadone maintenance treatment initiation.

Authors:  Will Damon; Will Small; Solanna Anderson; Lisa Maher; Evan Wood; Thomas Kerr; Ryan McNeil
Journal:  Drug Alcohol Rev       Date:  2016-04-29
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.